Skip to main content
IncyteEarnings

Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.

What happened

Incyte posted a GAAP net loss of $784.8 million for the third quarter of 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Incyte (INCY) reported third-quarter 2026 total GAAP revenue of $1.56 billion, up 14% from a year earlier. The company posted a GAAP net loss of $784.8 million, or $3.86 per basic and diluted share, driven in part by a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition. Total net sales rose 14% to $1.32 billion. Incyte raised its 2026 guidance for total net sales, Opzelura sales and Hematology and Oncology sales. $INCY insiders have traded $INCY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales. Here's a breakdown of recent trading of $INCY stock by insiders over the last 6 months: To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. We have seen 492 institutional investors add shares of $INCY stock to their portfolio, and 338 decrease their positions in their most recent quarter. Here are some of the largest recent moves: To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

quiverquant.com/news/Incyte+Reports+%241.56+Billion+Third-Quarter+Rev...Read the full source

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

Amount named
$785M

The full record

From the Signal API record

Numbers

Amount named in the story
$785M

Extraction

Confidence
95%
Detected
Oct 29, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/22ade81c-30aa-618c-7015-ace5a53550b9 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "22ade81c-30aa-618c-7015-ace5a53550b9",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-29T11:07:00+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.quiverquant.com/news/Incyte+Reports+%241.56+Billion+Third-Quarter+Revenue+and+Raises+2026+Sales+Guidance",
    "title": "Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance - Quiver Quantitative",
    "excerpt": "Incyte (INCY) reported third-quarter 2026 total GAAP revenue of $1.56 billion, up 14% from a year earlier. The company posted a GAAP net loss of $784.8 million, or $3.86 per basic and diluted share, driven in part by a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition. Total net sales rose 14% to $1.32 billion. Incyte raised its 2026 guidance for total net sales, Opzelura sales and Hematology and Oncology sales. $INCY insiders have traded $INCY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales . Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months: To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. We have seen 492 institutional investors add shares of $INCY stock to their portfolio, and 338 decrease their positions in their most recent quarter. Here are some of the largest recent moves: To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.",
    "summary": "Incyte posted a GAAP net loss of $784.8 million for the third quarter of 2026.",
    "planning": false,
    "image_url": "https://www.quiverquant.com/images/incy_rect_new.png",
    "confidence": 0.95,
    "published_at": "2026-10-29T11:07:00Z",
    "article_sentence": "The company posted a GAAP net loss of $784.8 million, or $3.86 per basic and diluted share, driven in part by a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition.",
    "amount_normalized": 784800000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.